Trial · NCT05422885
Results by group32
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 32
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Neurovascular Coupling | Dasatinib and Quercetin | Screening | 0.68 | Standard Deviation 1.40 | cm/s |
| Neurovascular Coupling | Dasatinib and Quercetin | Week 8 | 0.26 | Standard Deviation 2.04 | cm/s |
| Neurovascular Coupling | Dasatinib and Quercetin | Week 14 | 0.80 | Standard Deviation 2.13 | cm/s |
| Executive Function | Dasatinib and Quercetin | Baseline (Week 2) | 80.6 | Standard Deviation 80.2 | seconds |
| Executive Function | Dasatinib and Quercetin | Week 8 | 75.0 | Standard Deviation 61.4 | seconds |
| Executive Function | Dasatinib and Quercetin | Week 14 | 63.4 | Standard Deviation 44.6 | seconds |
| Gait Speed | Dasatinib and Quercetin | Baseline (Week 2) | 0.87 | Standard Deviation 0.15 | meters/second |
| Gait Speed | Dasatinib and Quercetin | Week 8 | 0.85 | Standard Deviation 0.16 | meters/second |
| Gait Speed | Dasatinib and Quercetin | Week 14 | 0.87 | Standard Deviation 0.14 | meters/second |
| Montreal Cognitive Assessment (MoCA) Score | Arm 1 | Baseline | 23 | Standard Deviation 2 | points |
| Montreal Cognitive Assessment (MoCA) Score | Arm 1 | 8 Weeks | 25 | Standard Deviation 3 | points |
| Montreal Cognitive Assessment (MoCA) Score | Arm 1 | 14 Weeks | 24 | Standard Deviation 2 | points |
| Physical Performance | Dasatinib and Quercetin | Baseline (Week 2) | 9 | Standard Deviation 1 | points |
| Physical Performance | Dasatinib and Quercetin | Week 8 | 9 | Standard Deviation 2 | points |
| Physical Performance | Dasatinib and Quercetin | Week 14 | 9 | Standard Deviation 2 | points |
| Mobility | Dasatinib and Quercetin | Baseline (Week 2) | 14.2 | Standard Deviation 2.6 | seconds |
| Mobility | Dasatinib and Quercetin | Week 8 | 13.9 | Standard Deviation 3.1 | seconds |
| Mobility | Dasatinib and Quercetin | Week 14 | 13.6 | Standard Deviation 2.4 | seconds |
| Grip Strength | Dasatinib and Quercetin | Baseline (Week 2) | 23.5 | Standard Deviation 7.2 | kilograms |
| Grip Strength | Dasatinib and Quercetin | Week 8 | 22.7 | Standard Deviation 5.8 | kilograms |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05422885/results